Viewing Study NCT04529473



Ignite Creation Date: 2024-05-06 @ 3:06 PM
Last Modification Date: 2024-10-26 @ 1:43 PM
Study NCT ID: NCT04529473
Status: COMPLETED
Last Update Posted: 2022-11-15
First Post: 2020-08-18

Brief Title: Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control
Sponsor: Atlantia Food Clinical Trials
Organization: Atlantia Food Clinical Trials

Study Overview

Official Title: A Double-blind Randomized Placebo-controlled Trial to Assess the Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Markers of Glycaemic Control in Healthy Hyperglycaemic Adults
Status: COMPLETED
Status Verified Date: 2022-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This 12 week placebo-controlled study evaluates the efficacy and safety of E hallii supplementation
Detailed Description: There is an increased awareness that the bacteria which forms our microbiome plays a crucial role in human health and diseases Numerous studies have highlighted the therapeutic potential of specific bacteria in preventing and treating metabolic gastrointestinal and other diseases

The aim of the study is evaluate the effect of administration of a next generation probiotic Eubacterium hallii versus placebo on insulin sensitivity and glycemic control in volunteers with some markers of metabolic syndrome

Participants will receive their randomized study product daily for 12 weeks The target population will be otherwise healthy hyperglycaemic adults

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None